What is CoMind?
CoMind Technologies Limited is at the forefront of redefining the measurement and treatment of brain functions to enhance patient outcomes across the healthcare continuum. The company is developing innovative technology that provides doctors with access to a wide range of critical neurophysiological signals through a single, simple, non-invasive bedside measurement. Their mission addresses a significant unmet need in neurotechnology, emphasizing non-invasive methods. CoMind aims to improve clinical practices and patient care through advanced photonics technology.
How much funding has CoMind raised?
CoMind has raised a total of $59M across 1 funding round:
Other Financing Round
$59M
Other Financing Round (2025): $59M with participation from Octopus Ventures, Angelini Ventures, LocalGlobe, Plural VC, and Latitude
Key Investors in CoMind
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing mission-driven companies across software, climate, health, consumer, and financial technology, offering long-term capital, guidance, and community.
Angelini Ventures
Angelini Ventures is a venture capital firm that invests in BioTech and HealthTech companies, focusing on transforming healthcare through technology and addressing unmet needs in vulnerable populations.
LocalGlobe
LocalGlobe is a venture capital firm known for its early-stage investments, often focusing on disruptive technologies and innovative business models.
What's next for CoMind?
With this substantial strategic investment, CoMind is poised to accelerate its development and market penetration. The enterprise-level funding suggests a focus on scaling operations, expanding research and development capabilities, and potentially forging new clinical partnerships. This capital will likely be instrumental in bringing their innovative non-invasive neurotechnology to a wider patient base, solidifying their position in the healthcare technology market and driving advancements in patient care.
See full CoMind company page
